➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Boehringer Ingelheim
McKesson
Baxter
Mallinckrodt

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

Adalimumab - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for adalimumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Vlaams Instituut voor Biotechnologie (VIB); Merck Sharp & Dohme (MSD)Phase 3
University Hospital, GhentPhase 3
Shanghai Zhongshan HospitalPhase 4

See all adalimumab clinical trials

Recent Litigation for adalimumab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Coherus Biosciences, Inc. v. Amgen Inc.2019-01-24
ABBVIE INC. v. SANDOZ INC.2018-08-10
Celgene Corporation v. Aurobindo Pharma Limited2018-07-06

See all adalimumab litigation

PTAB Litigation
PetitionerDate
Fresenius Kabi USA, LLC2019-09-17
2017-12-20
Sandoz Inc.2017-11-06

See all adalimumab litigation

Pharmacology for adalimumab

Patent Text Search: US Patents for adalimumab

These patents were identified by searching patent claims

Supplementary Protection Certificates for adalimumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
138 Luxembourg   Start Trial PRODUCT NAME: RITUXIMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20140326
C0001 France   Start Trial PRODUCT NAME: ADALIMUMAB; NAT. REGISTRATION NO/DATE: EU/1/03/257/001 20030901; FIRST REGISTRATION: LI - 56221 20030416
692 Luxembourg   Start Trial PRODUCT NAME: IBRUTINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI. FIRST REGISTRATION: 20141023
2016000093 Germany   Start Trial PRODUCT NAME: LBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945 20160526
3 5026-2016 Slovakia   Start Trial PRODUCT NAME: IBRUTINIB VO VSETKYCH FORMACH CHRANENYCH ZA- KLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/14/945 20160530
17C/054 Belgium   Start Trial PRODUCT NAME: KEVZARA - SARILUMAB; AUTHORISATION NUMBER AND DATE: EU/1/17/1196 20170627
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Dow
McKesson
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.